Regarding COX-2 classification (positive vs. negative), 44/77 (57.1%) tumors were positive, corresponding to 33/38 (86.8%) malignant and 11/39 (28.2%) benign tumors (Table 2). This evidence concerns the gene PTGS2 and benign neoplasm.